MUSCLE PERFORMANCE IMPROVEMENT COMPOUNDS

To provide a compound comprising at least two components, a first component being the nLG3 domain from the C-terminus of human agrin, at least one second component being selected from proteins or an antagonistic antibody that inhibit ActR2B-induced signaling activity in the presence of myostatin, th...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	ROBERTA SCHELLINO, OLENA BUTENKO, JAN WILLEM VRIJBLOED, MARINA MARIA BIODO
Format:	Patent
Sprache:	eng ; jpn
Schlagworte:	CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	To provide a compound comprising at least two components, a first component being the nLG3 domain from the C-terminus of human agrin, at least one second component being selected from proteins or an antagonistic antibody that inhibit ActR2B-induced signaling activity in the presence of myostatin, these components being linked by means of linking entities.SOLUTION: Such compounds are effective treatments for neuromuscular diseases and problems.SELECTED DRAWING: Figure 1 【課題】少なくとも２つの成分を含む化合物であって、第一の成分は、ヒトアグリンのＣ末端からのｎＬＧ３ドメインであり、少なくとも１つの第二の成分は、ミオスタチンの存在下、ＡｃｔＲ２Ｂ誘導性シグナル伝達活性を阻害するタンパク質またはアンタゴニスト抗体から選択され、これらの成分は、連結要素の手段によって連結されている、前記化合物。【解決手段】かかる化合物は、神経筋肉疾患および問題のための有効な処置である。【選択図】図１